NSE: AUROPHARMA | BSE: 524804

Slowing Down Stock

Download real time

1042.10 -27.50 (-2.57%)

Near 52W Low of ₹1010.00

899.5K NSE+BSE Volume

NSE 08 Aug, 2025 3:31 PM (IST)

60,525.3

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Dividend

Aurobindo Pharma Ltd. last dividend of ₹4.00 per share was given on 08 Aug 2025 See details

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Search Inside the pdf :

Aurobindo Pharma Ltd.

06 Aug 2025

1042.10

-2.57%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock with a TP of Rs 1,400/share.

Prabhudas Lilladhar decreased Buy price target of Aurobindo Pharma Ltd. to 1300.0 on 06 Aug, 2025.

Aurobindo Pharma Ltd.

06 Aug 2025

1042.10

-2.57%

Aurobindo Pharma (ARBP IN) Q1FY26 Result Update Weak...

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

Aurobindo Pharma's (ARBP) Q1FY26 EBITDA of Rs16.1bn (down 1% YoY) was 5% below our estimate led by lower US sales. Resultant our FY26 and FY27E EPS stands reduced by 5-10%. The company has maintained its 20-21% OPM guidance for FY26E despite gRevlimid sales loss. We expect margins and revenues to improve from H2FY26/FY27 with ramp up in PenG facility, Vizag pant commercialization and launches in US. We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

05 Aug 2025

1042.10

-2.57%

Growth in EU/ARV; margin contraction drags PAT

Buy: Aurobindo Pharma Ltd.

Recommendation Target

Motilal Oswal

Aurobindo Pharma (ARBP) delivered lower-than-expected performance for 1QFY26. While revenue was in line with estimates, EBITDA/PAT missed our estimates by 7%/8% for the quarter.

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

31 Jul 2025

1042.10

-2.57%

Stock Flash

Accumulate: Aurobindo Pharma Ltd.

Deven Choksey

Aurobindo Pharma’s wholly owned subsidiary, Aurobindo Pharma USA Inc., has entered into a definitive agreement with Lannett Seller Holdco, Inc. to acquire 100% membership interest in Lannett Company LLC.

Aurobindo Pharma Ltd. has lost -29.55% in the last 1 Year

Aurobindo Pharma Ltd.

31 Jul 2025

1042.10

-2.57%

Stock Flash

Accumulate: Aurobindo Pharma Ltd.

Deven Choksey

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

04 Jul 2025

1042.10

-2.57%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

with multiple regulatory milestones lined up in the coming quarters. Execution of the pipeline delivery and expansion initiatives is expected to support long-term value creation. Therefore, we maintain our rating on the stock at BUY, with rolledforward target price of Rs. 1,348, based on 17.5x FY27x Adj. EPS....

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

28 May 2025

1042.10

-2.57%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Axis Direct

We maintain our BUY recommendation on Aurobindo Pharma with a TP of Rs 1,500/share.

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

27 May 2025

1042.10

-2.57%

Aurobindo Pharma (ARBP IN) Q4FY25 Result Update Resumption...

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

Aurobindo Pharma's (ARBP) Q4FY25 EBITDA of Rs17.9bn (up 6% YoY) was in line with our estimate. FY26 guidance of high single digit revenue growth ex gRevlimid with flat margins was below our estimate. Resultant our FY26 and FY27E EPS stands reduced by 4-5%. Other expenses remained elevated on the back of higher PenG-related operational cost and supply disruptions due to...